BCL2 and esophageal squamous cell carcinoma: LncRNA PART1 in esophageal squamous cell carcinoma cell-derived EVs competitively combines with miR-129 to raise the expression of Bcl-2 in esophageal squamous cell carcinoma cells, thus inducing the drug resistance of tumor cells to gefitinib (106).